Curebound Facilitates Cancer Clinical Trials and AI Precision-Oncology Platform
|
Congratulations to Moores Members Irene Su, MD, MSCE, Paula Aristizabal, MD, Shweta Joshi, PhD, Andrew Lowy, MD, Ludmil Alexandrov, PhD, and Scott Lippman, MD for securing new Curebound investment to support their continued advancements in cancer research.
|
In this Q&A with the UC San Diego, School of Medicine, Department of Surgery, Diane Simeone, MD describes not only her journey to transform cancer care and passion for early detection, but also new standards in the fight against one of the deadliest cancers—pancreatic cancer.
|
|
|
Regulation of Human Skeletal Muscle Stem and Progenitor Cells In Vitro and In Vivo
|
Moores Member Catriona Jamieson, MD, PhD is hosting a Sanford Stem Cell Institute Seminar on Monday, September 9, 2024, from 3:00 p.m. to 4:00 p.m. in the Duane Roth Auditorium at the Sanford Consortium for Regenerative Medicine. April Pyle, PhD will present on (1) treating patients with stem cells more effectively and (2) recent clinical advances and research in stem cells and regenerative medicine.
|
|
|
Starting an Investigator-Initiated Trial (ITT) at Moores
|
On Tuesday, August 20, 2024, Moores held its first ITT training session: Navigating the Nuances: Essentials of Operationalizing IITs. Fifty-six attendees joined this review of the new operational workflow for IITs at UC San Diego.
If you are interested in starting an IIT at Moores, then feel free to watch the recording of the session at the link below.
|
Moores will launch an in-depth IIT training course this fall, in addition to providing Part 1 of the bi-annual PI training.
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Department of Defense (DOD), Congressionally Directed Medical Research Programs (CDMRP)
|
The DOD CDMRP Glioblastoma Research Program (GBMRP) has released a pre-announcement for the following funding opportunities:
|
- Hypothesis Development Award
- Resource Development Award
|
Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1 Clinical Trial Required)
|
Through this Notice of Funding Opportunity (NOFO), the NCI will support CP-CTNet sites to achieve the following objectives:
|
- Design and conduct early-phase clinical trials that (1) assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, which target molecules or processes known to be important during carcinogenesis and (2) comprise Phase 0 (micro-dosing), Phase I (dose-finding), and Phase II (preliminary efficacy) trials.
-
Characterize the effects of these agents and interventions on their molecular targets and other biological events associated with cancer development (e.g., cell proliferation, apoptosis, growth factor expression, oncogene expression, and immune response); correlate these effects with clinical endpoints.
-
Determine the mechanisms of cancer prevention by the agents examined, which includes the development of novel potential markers as determinants of response.
|
LOI Deadline: August 23, 2024
Application Deadline: October 31, 2024
|
Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)
|
Through this NOFO, the NCI will support the AIDS AMC, which is a multi-center infrastructure intended to stimulate cooperative research efforts in the following areas:
|
- Design, development, and evaluation of clinical interventions for the prevention and treatment of malignancies in people with HIV (PWH)
- Development of more effective therapeutics and management strategies for malignancies in PWH
- Investigation of the biology of HIV malignancies within the context of clinical trials
-
Management of issues of international importance in malignancies in PWH
- Distribution of excess tumor tissue and other relevant biologic fluids to the AIDS and Cancer Specimen Resource for ongoing or future investigations.
|
A proposed AMC must feature an Operations Center, Clinical Trial Sites, Network Laboratories, and a Statistical Center. A proposed AMC team must comprise scientific disease-oriented Working Groups to study Kaposi sarcoma, hematologic malignancies, HPV-associated cancers, and solid tumors in PWH. Proposed Network Laboratories will be responsible for routine clinical trial support activities, pathogenesis-driven correlative studies, and clinical pharmacology and pharmacokinetics studies of anticancer/antiviral interactions. All clinical trials to be conducted by the AMC must be available to members of all racial/ethnic groups.
|
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 and R21 Clinical Trial Optional)
|
Through this NOFO, the NCI will support research that (1) examines the confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer, (2) assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer, (3) leverages stigma reduction interventions to ameliorate modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer, and (4) promotes research in domestic and international contexts, emphasizing regions in which the HIV-cancer burden is elevated.
|
|
| | Delivery systems developed for treatment combinations to improve adoptive cell therapy
|
Jinghong Li, MD, PhD (Cancer Biology and Signaling)
|
|
|
| Identification of leukemia stem cell subsets with distinct transcriptional, epigenetic, and functional properties
|
Jean Y. J. Wang, PhD (Cancer Biology and Signaling)
|
| |
| RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening
|
Samuel A. Myers, PhD (Cancer Biology and Signaling)
|
|
|
| Zfp697 is an RNA-binding protein that regulates skeletal muscle inflammation and remodeling
|
The Proceedings of the National Academy of Sciences (PNAS)
|
Gene W. Yeo, PhD (Structural and Functional Genomics)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
TSCAN-002: A Phase I Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors |
PI: Sandip Patel, MD
NCT: NCT05973487
| |
|
|
